Algenpantucel-L

Drug Profile

Algenpantucel-L

Alternative Names: HyperAcute Pancreas; Pancreatic cancer vaccine - NewLink Genetics

Latest Information Update: 04 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NewLink Genetics Corporation
  • Class Cancer vaccines; Cell therapies; DNA vaccines; Tumour cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase III Pancreatic cancer

Most Recent Events

  • 30 Jun 2016 NewLink Genetics terminates a phase II trial in Pancreatic cancer (Combination therapy) in USA (NCT02405585)
  • 09 May 2016 NewLink Genetics does not meet the primary endpoint in a phase III IMPRESS trial in Pancreatic cancer
  • 15 Dec 2015 NewLink Genetics completes enrolment in the phase III PILLAR trial in Pancreatic cancer (Combination therapy, Inoperable/Unresectable) in USA (NCT01836432)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top